Clinical Trial Update: Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease [EARLY_Phase 1]

View source ↗

Summary

An early Phase 1 clinical trial evaluating the addition of cord blood–derived mesenchymal stromal cells to ruxolitinib for treating steroid-refractory acute gra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Hematologic Malignancy

Drugs mentioned

• Cord Blood Tissue-Derived Mesenchymal Stromal Cells
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Steroid Refractory Graft Versus Host Disease | EARLY_Phase 1 | Status: RECRUITING